edit-301,dostarlimab
gsk,editas medicine, inc.
['dostarlimab', 'gyn', 'ruby']
 addition of dostarlimab to chemotherapy in the ruby trial - pfs consistently improved progression free survival for pts w/ #endometrialcancer in the blinded independent central review - the data remain c/w with the nejm study! #asco23 #gyncsm #immunoonc #immunotherapy 
Gyn Onc at MD Anderson. She/Hers. Wife of @DrJasonWestin. Innovative clinical trials. @ASCO_JCO social media editor. Opinions=mine.
https://t.co/QLXLDKSThc